Advanced and sustainable patient-centric healthcare
- Creation of innovative drugs and services, powered by unique strength in science and technology
- Provision of individualized and optimal solutions to patients
- Access to healthcare
- Quality assurance and stable supply of products and services
- Safety of patients and clinical trial participants
- Co-creation of a healthcare ecosystem with society and community
Why Chugai prioritizes “patient-centric”
Chugai values prioritizing the wellbeing of each and every
patient–
that is “patient-centric.”
Chugai has placed “patient-centric” as one of the most important core values in our mission statement (corporate philosophy), demonstrating our commitment to conducting business with the wellbeing of each and every patient as our top priority.
Chugai's goal is to “realize advanced, sustainable patient-centric healthcare.” By creating innovative pharmaceuticals, we hope to contribute to the advancement of patient-centric healthcare while also growing as a company.
Core Values
-
1. Patient Centric
Make each patient’s wellbeing our highest priority
-
2. Pioneering Spirit
Pursue innovation by improving ourselves and thinking differently
-
3. Integrity
Maintain the highest standards in all we do to create shared value with society
Relationship to Material Issues
“Material issues” is a term used to describe important issues that a company should prioritize.
To realize sustainable patient-centric healthcare, Chugai determines issues that need to be resolved from the perspective of patients and society through dialogue with diverse stakeholders.
Material issues related to advanced and sustainable patient-centric healthcare
Creation of innovative drugs and services, powered by unique strength in science and technology
To realize advanced and sustainable healthcare, continuously
create innovative, high-quality drugs and services that
address unmet medical needs. To achieve this, we will create
original technologies mainly for drug discovery, and cultivate
understanding of science and biology for disease.
Based
on our value of patient-centricity, we aim to provide drugs
and services that are centered on patients and reduce burdens
on people around them such as caregivers and healthcare
professionals and improve their QOL. To this end, we will
actively adopt advanced technologies such as digital
technology, and continuously work together with people around
world on sophistication and acceleration of business processes
for value creation, collaborate with academia, open
innovation, advanced use of intellectual property, etc.
Quality assurance and stable supply of products and services
To provide reliable products and services that customers can use with confidence, we will ensure consistent and stable products and services, as well as information quality, throughout the product life cycle from the clinical trial stage. We will also make efforts to prevent counterfeiting and poor quality of drugs, such as enhancing traceability in the supply chain. In addition, in accordance with the basic concept of quality, we will build a supply chain that is robust even in emergencies by working together with stakeholders in the value chain.
Provision of individualized and optimal solutions to patients
We will generate evidence that enhances value for patients,
continuously working to provide solutions that meet the
diverse needs of individual patients and medical practices to
strengthen and advance them.
Contribute to the provision
of healthcare that is optimal for each patient and truly
enhances value together with stakeholders involved in
healthcare such as patients, their families, and healthcare
professionals.
Safety of patients and clinical trial participants
To ensure thorough management of safety throughout the product
lifecycle and minimize potential negative impact such as
deteriorating health to patients and clinical trial subjects.
In addition to carrying out appropriate pharmacovigilance
activities in cooperation with regulatory authorities, we
ensure the provision of information to healthcare
professionals to promote the proper use of drugs and
services.
Particularly in ensuring the safety of products
and conducting clinical studies on development products, risks
and efficacy shall be appropriately evaluated from the
viewpoints of high ethics and science.
Access to healthcare
We will contribute to regional healthcare coordination and enhancement of healthcare so that highly specialized medical care, mainly comprising innovative drugs and services that address unmet medical needs, can be delivered to people around the world who need it. We will realize continuous and sustainable creation of drugs and services by obtaining appropriate recognition for the provision of innovative drugs and services that have true value while taking measures such as cost reduction by proactive use of new technologies and promotion of treatment design with less burden for patients.
Co-creation of a healthcare ecosystem with society and community
In order to support the foundation for sustainable
patient-centric and advanced healthcare, and to expand healthy
society, we collaborate with various entities such as
society/community, patient group, government, administration,
to create collective impact against social issues related to
healthcare that cannot be solved by our company alone.
Through
this, we will contribute to the maintenance, expansion and
development of a robust foundation and ecosystem that supports
medicine and healthcare as a leader in the industry.
Overview of “Patient-Centric” Initiatives
With material issues as a basis,
we are working to solve
issues by dividing our activities into three areas
Chugai's “patient-centric” initiatives are classified into three categories based on material issues, according to the scope and extent of their activities.
At the core of our activities are those aimed at increasing the value we provide to patients through our products and services. This is Chugai's core business, and we have been striving to continually evolve it by incorporating patient feedback.
In addition to these activities, we are also engaged in activities based on collaboration with patient organizations, positioning patients as partners. Through dialogue, we are also pursuing a new approach that incorporates collaboration with patient organizations into all parts of the value chain, including drug discovery and development.
Through these efforts, we also engage directly with patients and society and carry out awareness-raising activities.
Initiatives
With the creation of innovative pharmaceuticals and services at its core, Chugai is striving to evolve all functions, including drug discovery, development, production, marketing, safety, and quality assurance, with the aim of providing solutions that are truly valuable to patients and contributing to healthcare itself.
The “patient-centric” activities we are particularly focusing on are summarized below by business process. Please refer to the related links for more detailed information and examples.
| Drug discovery | |||
|---|---|---|---|
|
“Patient-centric” business activities
Initiatives in partnership with patients and patient organizations Engagement with patients, healthcare, and society |
|||
|
Creation of new drugs to address unmet medical needs*1 (discovery of new targets and development of new modalities*2 such as middle molecules) (Related Link) |
|||
|
Survey and dialogue regarding patients and medical needs |
|||
|
Building a new drug discovery scheme that reflects the voices of patients |
|||
| Development | |||
|---|---|---|---|
|
“Patient-centric” business activities
Initiatives in partnership with patients and patient organizations Engagement with patients, healthcare, and society |
|||
|
Objective and quantitative visualization of patient evaluations of emotions, pain, etc., and demonstration of true value (True Endpoint) (Related link) |
|||
|
Taking on the challenge of new clinical trial methods that reduce the burden on subjects (Related link) |
|||
|
Initiatives aimed at improving the success rate of clinical trials by determining optimal dosage and improving the predictability of efficacy and safety (Related link) |
|||
|
Promotion of ePRO (Electronic Patient-Reported Outcome system) (Related link) |
|||
|
Orphan drug development |
|||
|
Initiatives to incorporate patient perspectives and opinions into drug development and to widely disseminate information about clinical trials (Related Link) |
|||
|
Taking on the challenge of simultaneous development of new drugs for multiple diseases with the aim of rapid provision of new drugs |
|||
| Production | |||
|---|---|---|---|
|
“Patient-centric” business activities
Initiatives in partnership with patients and patient organizations Engagement with patients, healthcare, and society |
|||
|
Building a production system for the rapid delivery of new drugs (Related Link) |
|||
|
Stable supply of patient-centric products (Related Link) |
|||
|
Smart factory initiatives to quickly respond to demand (Related Link) |
|||
|
Establishment and operation of a global-level pharmaceutical quality system (Related Link) |
|||
|
Anti-Counterfeit Measures Since entering into a strategic alliance with Roche, Chugai has not only been importing products into Japan, but has also been exporting its original products overseas, so it has been working on supply-chain security measures on a global scale as well as in Japan. |
|||
|
Design and development of dosage forms, devices and packaging for drug products that take into consideration ease of administration and use |
|||
| Solutions | |||
|---|---|---|---|
|
“Patient-centric” business activities
Initiatives in partnership with patients and patient organizations Engagement with patients, healthcare, and society |
|||
|
Disclosure of information on pharmaceuticals, safety, clinical trials, etc. The Chugai Group strives to provide high-quality pharmaceuticals as well as high-quality information to patients and healthcare professionals in a timely and accurate manner so that they can be used appropriately. (Related Link) |
|||
|
Formulating guidelines for providing timely information to patients |
|||
|
Drug Safety Improvement Initiatives Chugai works on drug safety activities based on three strategic points: 1) maximization of the value of growth drivers through thorough promotion of appropriate use, 2) generation of unique evidence to contribute to personalized healthcare (PHC) and building of innovative customer engagement models, and 3) maximization of product value through enhancement of safety measures from the clinical development stage. |
|||
|
Initiatives to develop patient-centric local medical care |
|||
|
Activities to improve literacy among patients and the general public (Related Link) |
|||
|
Advocacy Support (Related link) |
|||
|
Global Health Initiatives to Improve Access to Healthcare (Related Link) |
|||
- *1 An unmet medical need for which there is still no effective treatment
- *2 The physical type of drug (low molecular-weight drugs, antibody drugs, middle molecule drugs, etc.)
Collaboration with Patient Groups
We believe that patient-centric healthcare means healthcare in
which patients participate in healthcare so that each patient
can choose the treatment most appropriate for him/her. To that
end, we need to establish an environment in which patients can
enhance their medical literacy, communicate with healthcare
professionals to manage their disease by themselves, and
deliver the patient's voice to the field of healthcare and
policy.
To solve these issues, Chugai values collaboration with
patient groups that represent the patient voice. We are making
company-wide efforts to realize patient-centric healthcare. We
have identified three pillars and eight issues in
collaboration with patient organizations through active
dialogue, including dialogue between our company Management
and representatives of several patient organizations.
